← FDA Drug Approvals (Drugs@FDA)

QTERN

NDA · New Drug Application · Sponsor: ASTRAZENECA AB · Approved 2017-02-27

Drug application

FDA Application #

NDA209091

Application type

New Drug Application

Brand name

QTERN

Generic name

Dapagliflozin

Active ingredients

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

Dosage form

TABLET

Route

ORAL

Marketing status

Discontinued

Sponsor

ASTRAZENECA AB

First approval

2017-02-27

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown